CCL2 and breast carcinoma: Caution is likely needed in clinical translation of CCL2/CCR2‐targeted therapies, as discontinuation of anti‐CCL2 therapy enhances metastasis in mouse experimental models of breast cancer.125 Blocking pro‐tumorigenic cues derived from monocyte‐derived cells such as IL‐6 and VEGF may be one strategy to prevent adverse effects caused by termination of anti‐CCL2 therapy.125